News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
343,771 Results
Type
Article (27541)
Company Profile (162)
Press Release (316058)
Multimedia
Podcasts (44)
Webinars (17)
Section
Business (92918)
Career Advice (1334)
Deals (14461)
Drug Delivery (94)
Drug Development (38912)
Employer Resources (160)
FDA (8347)
Job Trends (8757)
News (156336)
Policy (13857)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2014)
Academic (2)
Accelerated approval (19)
Adcomms (17)
Allergies (116)
Alliances (25691)
ALS (115)
Alzheimer's disease (1055)
Antibody-drug conjugate (ADC) (164)
Approvals (8615)
Artificial intelligence (355)
Autoimmune disease (89)
Automation (28)
Bankruptcy (102)
Best Places to Work (7415)
BIOSECURE Act (13)
Biosimilars (112)
Biotechnology (92)
Bladder cancer (105)
Brain cancer (30)
Breast cancer (365)
Cancer (2611)
Cardiovascular disease (257)
Career advice (1194)
Career pathing (39)
CAR-T (159)
CDC (24)
Celiac Disease (1)
Cell therapy (446)
Cervical cancer (26)
Clinical research (33734)
Collaboration (1117)
Compensation (439)
Complete response letters (28)
COVID-19 (1491)
CRISPR (67)
C-suite (618)
Cystic fibrosis (125)
Data (3996)
Decentralized trials (1)
Denatured (25)
Depression (86)
Diabetes (306)
Diagnostics (3585)
Digital health (26)
Diversity (10)
Diversity, equity & inclusion (39)
Drug discovery (161)
Drug pricing (89)
Drug shortages (7)
Duchenne muscular dystrophy (135)
Earnings (28919)
Editorial (29)
Employer branding (24)
Employer resources (138)
Events (52465)
Executive appointments (710)
FDA (10390)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (6)
Frontotemporal dementia (9)
Funding (1008)
Gene editing (135)
Generative AI (34)
Gene therapy (406)
GLP-1 (528)
Government (2472)
Grass and pollen (2)
Guidances (224)
Healthcare (10079)
HIV (41)
Huntington's disease (28)
IgA nephropathy (62)
Immunology and inflammation (117)
Immuno-oncology (18)
Indications (54)
Infectious disease (1641)
Inflammatory bowel disease (141)
Inflation Reduction Act (9)
Influenza (61)
Intellectual property (125)
Interviews (201)
IPO (6536)
IRA (27)
Job creations (1610)
Job search strategy (1021)
JPM (35)
Kidney cancer (3)
Labor market (82)
Layoffs (238)
Leadership (25)
Legal (2257)
Liver cancer (52)
Longevity (12)
Lung cancer (329)
Lymphoma (237)
Machine learning (29)
Management (53)
Manufacturing (467)
MASH (78)
Medical device (6735)
Medtech (6764)
Mergers & acquisitions (8558)
Metabolic disorders (689)
Multiple sclerosis (95)
NASH (12)
Neurodegenerative disease (190)
Neuropsychiatric disorders (40)
Neuroscience (1851)
Neurotech (1)
NextGen: Class of 2026 (3753)
Non-profit (3488)
Now hiring (64)
Obesity (293)
Opinion (182)
Ovarian cancer (91)
Pain (126)
Pancreatic cancer (109)
Parkinson's disease (198)
Partnered (28)
Patents (215)
Patient recruitment (288)
Peanut (51)
People (35087)
Pharmaceutical (38)
Pharmacy benefit managers (8)
Phase 1 (9754)
Phase 2 (14513)
Phase 3 (12467)
Pipeline (3093)
Policy (144)
Postmarket research (1246)
Preclinical (4282)
Press Release (61)
Prostate cancer (145)
Psychedelics (28)
Radiopharmaceuticals (140)
Rare diseases (607)
Real estate (3273)
Recruiting (63)
Regulatory (11712)
Reports (47)
Research institute (1800)
Resumes & cover letters (171)
Rett syndrome (26)
RNA editing (11)
RSV (55)
Schizophrenia (99)
Series A (175)
Series B (120)
Service/supplier (7)
Sickle cell disease (69)
Special edition (13)
Spinal muscular atrophy (117)
Sponsored (30)
Startups (2412)
State (1)
Stomach cancer (9)
Supply chain (59)
Tariffs (23)
The Weekly (19)
Vaccines (488)
Venture capital (73)
Weight loss (177)
Women's health (48)
Worklife (20)
Date
Last 7 days (346)
Last 30 days (1279)
Last 365 days (17615)
2026 (1708)
2025 (17904)
2024 (20381)
2023 (22765)
2022 (28074)
2021 (31157)
2020 (28800)
2019 (25558)
2018 (19022)
2017 (16615)
2016 (16122)
2015 (17745)
2014 (12883)
2013 (10439)
2012 (10969)
2011 (11340)
2010 (10218)
Location
Africa (505)
Alabama (51)
Alaska (7)
Arizona (152)
Arkansas (9)
Asia (19812)
Australia (3550)
California (6303)
Canada (1757)
China (539)
Colorado (277)
Connecticut (284)
Delaware (261)
Europe (49400)
Florida (1006)
Georgia (234)
Hawaii (3)
Idaho (24)
Illinois (448)
India (53)
Indiana (417)
Iowa (20)
Japan (345)
Kansas (63)
Kentucky (26)
Louisiana (19)
Maine (16)
Maryland (721)
Massachusetts (4794)
Michigan (214)
Minnesota (351)
Mississippi (6)
Missouri (69)
Montana (19)
Nebraska (11)
Nevada (72)
New Hampshire (22)
New Jersey (1950)
New Mexico (19)
New York (1778)
North Carolina (953)
North Dakota (9)
Northern California (3090)
Ohio (205)
Oklahoma (12)
Oregon (29)
Pennsylvania (1234)
Puerto Rico (13)
Rhode Island (25)
South America (639)
South Carolina (15)
Southern California (2397)
Tennessee (84)
Texas (878)
United States (23011)
Utah (156)
Vermont (1)
Virginia (136)
Washington D.C. (52)
Washington State (418)
West Virginia (2)
Wisconsin (93)
Wyoming (1)
343,771 Results for "wave life sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 antitrypsin deficiency landscape is coming into focus, with Wave and Beam Therapeutics leading the way.
February 2, 2026
·
3 min read
·
Heather McKenzie
Rare diseases
GSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study.
February 2, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
February 2, 2026
·
7 min read
Press Releases
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
·
1 min read
Weight loss
Wave Soars on Early Results for Obesity Treatment That Could ‘Disrupt’ the Landscape
Although still in Phase I, Wave Life Sciences’ injectable RNA weight loss treatment achieved results that impressed analysts, with 4% fat reduction after three months, beating Novo Nordisk’s semaglutide at a similar time point.
December 8, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Wave Life Sciences to Present at Upcoming November 2025 Investor Conferences
November 10, 2025
·
2 min read
Press Releases
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 9, 2025
·
5 min read
Press Releases
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
November 10, 2025
·
19 min read
Press Releases
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
November 5, 2025
·
1 min read
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
December 8, 2025
·
3 min read
1 of 34,378
Next
